 | • レポートコード：MRC2203A106 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の心臓補助装置市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（大動脈内バルーンポンプ、全人工心臓（TAH）、心室補助装置）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の心臓補助装置市場規模：製品別（大動脈内バルーンポンプ、全人工心臓（TAH）、心室補助装置） ・世界の心臓補助装置市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abbott Laboratories、Abiomed Inc.、Berlin Heart GmbH、…） ・市場機会・将来傾向 |
The demand for cardiac assist devices has increased in the last few years, as these devices help in the continuous flow of blood to the heart and require no mechanical bearings. It also acts as a bridge in transplant, are available in miniature sizes, and are the life-line support for heart patients, assisting them in in recovering from or while waiting for a heart transplant. In March 2015, the US FDA approved the Impella 2.5 System, which helps the patients in maintaining a stable heart function and circulation, during certain high-risk percutaneous coronary intervention (HRPCI) procedures. The variety of reliable ventricular assist devices (VAD) has increased, as technology has advanced, promising better treatment options for patients. In addition, the government support has also increased the funding for research and development initiatives in advanced medical treatment options, placing utmost concern to the safety of patients.
Other factors such as rising geriatric population and increasing heart diseases prevalence are expected to drive the market in the forecast period.
Key Market Trends
Total Artificial Heart Segment is Expected to Show Better Growth in the Forecast Years
Based on product, it is segmented into Intra-aortic Balloon Pump, Total Artificial Heart, and Ventricular Assist Device. Heart transplantation is the most effective treatment for end-stage heart failures. Globally, there has been an increase in the demand for donor organs. According to the United States Department of Health and Human Services, there were approximately 17,553 donors in 2018. Moreover, there has been an exponential rise in the demand for artificial hearts in the market. It is estimated that nearly 4,000 individuals wait for a donor’s heart daily in the United States alone. The total artificial heart is considered a long-term solution for patients suffering from advanced heart failure issues. There are currently, many different types of artificial hearts in the market that are being used: SynCardia temporary total artificial heart and Abiocar artificial heart. Thus, the availability of these products is expected to drive the market, globally.
North America Dominates the Cardiac Assist Devices Market
North America region is among the major contributor in this market due to the advancements in technology, and the increasing burden of heart diseases. According to the Centers for Disease Control and Prevention (CDC), about 647,000 Americans die from heart disease each year. The increasing number of individuals with heart diseases leads to a higher demand. Over 30% of global LVAD implants are being performed in the United States, and the number of implants is increasing year by year. Hence, the high adoption rate for these devices is expected to increase the cardiac assist devices market significantly during the forecast.
Competitive Landscape
The global players in the cardiac assist devices market are – Abbott Laboratories, Abiomed Inc., Berlin Heart GmbH, BiVACOR Inc., Braile Biomedica Ltd, Getinge AB, Jarvik Heart Inc., Medtronic PLC, SynCardia Systems, LLC, and Teleflex Incorporated.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Heart Disease Prevalence
4.2.2 Rising Geriatric Population
4.2.3 Technological Advancement
4.3 Market Restraints
4.3.1 Availability of Alternative Treatments like Pacemakers
4.3.2 Risk Associated with Device Implantation
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Intra-aortic Balloon Pump
5.1.2 Total Artificial Heart
5.1.3 Ventricular Assist Device
5.1.3.1 Left Ventricular Assist Device
5.1.3.2 Right Ventricular Assist Device
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Abiomed Inc.
6.1.3 Berlin Heart GmbH
6.1.4 BiVACOR Inc.
6.1.5 Braile Biomedica Ltd
6.1.6 Getinge AB
6.1.7 Jarvik Heart Inc.
6.1.8 Medtronic PLC
6.1.9 SynCardia Systems, LLC
6.1.10 Teleflex Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS